Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Sep 28, 2018 in Leukemia | 0 comments

In a nutshell

This study looked at updates on the safety and effectiveness of gemtuzumab ozogamicin (Mylotarg) in the treatment of acute myeloid leukemia (AML). Researchers found that a low dose of gemtuzumab ozogamicin in addition to standard chemotherapy was safe and effective in the treatment of AML.

Some background

Acute myeloid leukemia is a cancer of the bone marrow which affects the immune system. It is often treated with a variety of chemotherapy drugs that can have varied safety and effectiveness. Up-to-date research on these medications is important to best treat patients with AML.

Methods & findings

Two hundred and eighty patients were included in the study. Half of these patients were chosen at random to receive standard chemotherapy with a control (a false treatment for comparison). The other half received standard chemotherapy with gemtuzumab ozogamicin (GO). These treatments were given at Day 1, 4, and 7.

Patients who received GO were 66% more likely to survive without complications from the disease (event-free survival). Evidence showed that patients who received GO may have had an increased overall survival but this was not significant.  

Side effects occurred in 41 (31.3%) patients who received GO. The most common included a low platelet count (blood cells involved with clotting) in 20 (15.3%) patients, and liver problems in 8 (6.1%) patients.

The bottom line

The study concluded that overall, gemtuzumab ozogamicin was a safe and effective addition to standard chemotherapy for patients with AML.

What’s next?

Discuss with your doctor about the possibility of adding gemtuzumab ozogamicin to your treatment plan for AML.

Published By :


Date :

Aug 03, 2018

Original Title :

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial.

click here to get personalized updates